Biohaven Ltd. (BHVN) |
| 10.37 -0.07 (-0.67%) 04-15 16:00 |
| Open: | 10.56 |
| High: | 10.77 |
| Low: | 10.19 |
| Volume: | 1,960,862 |
| Market Cap: | 1,098(M) |
| PE Ratio: | -1.51 |
| Exchange: | New York Stock Exchange |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.73 |
| Resistance 1: | 10.90 |
| Pivot price: | 9.28 |
| Support 1: | 9.13 |
| Support 2: | 8.03 |
| 52w High: | 24.06 |
| 52w Low: | 7.48 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Financials
| EPS | -6.860 |
| Book Value | 0.390 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.0 |
| Return on Equity (ttm) | -310.8 |
Company news
Thu, 16 Apr 2026
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wed, 15 Apr 2026
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha
Wed, 15 Apr 2026
Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN
Wed, 15 Apr 2026
Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN
Mon, 13 Apr 2026
Biohaven (NYSE:BHVN) Stock Price Up 10.2% - What's Next? - MarketBeat
Mon, 13 Apr 2026
Biohaven (NYSE:BHVN) Now Covered by Canaccord Genuity Group - MarketBeat
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
